• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Study shows favorable results for Sculptra Aesthetic

Bridgewater, N.J. - Recently released results of a new study suggest that treatment with Sculptra Aesthetic (poly-L-lactic acid, Sanofi-Aventis) is significantly more effective than the human-derived collagen treatment CosmoPlast (Allergan) in correcting shallow to deep nasolabial folds, PR Newswire reports.

Bridgewater, N.J.

- Recently released results of a new study suggest that treatment with Sculptra Aesthetic (poly-L-lactic acid, Sanofi-Aventis) is significantly more effective than the human-derived collagen treatment CosmoPlast in correcting shallow to deep nasolabial folds, PR Newswire reports.

The study, published in the Feb. 23 online edition of the Journal of the American Academy of Dermatology, suggests that in addition to efficacy, correcting wrinkles with Sculptra Aesthetic can last for as long as 25 months.

In the study, 233 patients age 26 to 73 were randomized to receive standard-of-care injections of either Sculptra Aesthetic or CosmoPlast dermal filler in the left and right nasolabial folds at three-week intervals for up to a maximum of four treatments. Patients were followed for 13 months after the final treatment.

According to the study, treatment with Sculptra Aesthetic resulted in significantly higher scores than treatment with CosmoPlast on the wrinkle assessment scale. Sculptra Aesthetic treatment effects were maintained up to 25 months after the last treatment session, while the human-derived collagen was effective up to three months.

Most adverse events in both groups were mild or moderate in intensity, according to the study.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.